Valuation: Scienture Holdings, Inc.

Market Cap 3.74M 3.41M 3.14M 2.86M 5.36M 346M 5.63M 38.22M 15.19M 189M 14.04M 13.74M 594M P/E 2026 *
-0.24x
P/E 2027 * -0.65x
Enterprise Value 3.74M 3.41M 3.14M 2.86M 5.36M 346M 5.63M 38.22M 15.19M 189M 14.04M 13.74M 594M EV / Sales 2026 *
1.2x
EV / Sales 2027 * 0.24x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-6.45%
1 week-21.45%
Current month-29.26%
1 month-21.59%
3 months-79.74%
6 months-77.22%
Current year-82.13%
1 week 2
Extreme 2.0001
3.27
1 month 2
Extreme 2.0001
3.68
Current year 2
Extreme 2.0001
16.11
1 year 2
Extreme 2.0001
18.75
3 years 2
Extreme 2.0001
335.5
5 years 2
Extreme 2.0001
335.5
10 years 2
Extreme 2.0001
335.5
Date Insider Type Main position Quantity % Market Cap. Importance
19/09/24 Conversion

Director

2,927,538 -
19/09/24 Conversion

Chief Executive Officer

3,853,296 -
25/07/24 Other

Director

57,977 4.1225%
Change 5-day change 1-year change 3-year change Capi.($)
-6.45%-21.45%-82.75% - 3.74M
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average -0.35%-6.19%+14.24%+75.64% 407B
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%

Financials

2026 *2027 *
Net sales 3.11M 2.83M 2.61M 2.37M 4.45M 288M 4.68M 31.76M 12.62M 157M 11.66M 11.42M 494M 15.47M 14.09M 12.98M 11.81M 22.16M 1.43B 23.29M 158M 62.81M 782M 58.05M 56.82M 2.46B
Net income -15.33M -13.96M -12.86M -11.7M -21.95M -1.42B -23.07M -157M -62.23M -775M -57.51M -56.3M -2.43B -6.27M -5.71M -5.26M -4.78M -8.98M -580M -9.43M -64.01M -25.44M -317M -23.51M -23.02M -995M
Net Debt - -
Projected Income Statement - Annual - Scienture Holdings, Inc.
Logo Scienture Holdings, Inc.
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Employees
7
Date Price Change Volume
20/11/26 US$2.278 -6.45% 29,858
19/11/26 US$2.435 -4.51% 38,586
18/11/26 US$2.550 -7.61% 91,089
17/11/26 US$2.760 -7.69% 15,460
16/11/26 US$2.990 +3.10% 89,385
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.278USD
Average target price
6.000USD
Spread / Average Target
+163.40%
  1. Stock Market
  2. Stocks
  3. SCNX Stock